Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who had a body mass index 18 to \< 35 kg/m\^2.~* Females were either postmenopausal for at least 2 years, surgically sterile, or willing to use at least 2 effective forms of birth control.~* Males must have been surgically sterile or agreed to use at least 2 effective forms of birth control throughout the course of the study.~* Participants were in a condition of general good health, other than the HCV infection.~* Participants had a chronic HCV genotype 1, 2, or 3 infection for at least 6 months, a plasma HCV RNA \> 50,000 IU/mL, and FibroTest score \<= 0.72 and aspartate aminotransferase (AST) to platelet ratio index \<= 2, Fibroscan® result of \< 9.6 kilopascal (kPa), or absence of cirrhosis based on a liver biopsy.~Exclusion Criteria:~* Positive drug screen~* Previous use of anti-HCV agents~* History of cardiac disease~* History of uncontrolled diabetes or diabetes requiring insulin~* Abnormal laboratory results~* Females who were pregnant or planned to become pregnant within 6 months after their last dose of study drug/RBV or were breastfeeding; males whose partners were pregnant or would become pregnant within 6 months after their last dose of study drug/RBV~* Positive test result for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus (HIV) antibody (Ab). Negative HIV status was to be confirmed at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ABT-450/r and ABT-267 plus RBV in genotype 1 participants (Type: EXPERIMENTAL): ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided twice daily (BID) in treatment-naïve participants with HCV genotype 1 infection.
- ABT-450/r and ABT-267 plus RBV in genotype 2 participants (Type: EXPERIMENTAL): ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 2 infection.
- ABT-450/r and ABT-267 plus RBV in genotype 3 participants (Type: EXPERIMENTAL): ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 3 infection.
- ABT-450/r and ABT-267 in genotype 1 participants (Type: EXPERIMENTAL): ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 1 infection.
- ABT-450/r and ABT-267 in genotype 2 participants (Type: EXPERIMENTAL): ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 2 infection.
- ABT-450/r and ABT-267 in genotype 3 participants (Type: EXPERIMENTAL): ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 3 infection.

Based on this trial design, predict the completion outcome and termination type (if applicable).